Lee Seung-Jae, Zhou Tianjun, Goldsmith Elizabeth J
Department of Biochemistry, The University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Dallas, TX 75390-8816, USA.
Methods. 2006 Nov;40(3):224-33. doi: 10.1016/j.ymeth.2006.05.003.
X-ray structural studies of MAP kinases and MAP kinase module components are elucidating how kinase activity is regulated and how specificity of signaling is conferred. In the past decade, MAP kinases have been crystallized in their active, phosphorylated forms or low-activity, unphosphorylated forms, as well as in the presence of binding partners such as docking peptides and inhibitors. Crystallization has been achieved via diverse strategies including control of phosphorylation, coding sequence modification, incorporation of tags for purification, and use of a variety of cell-types for protein expression. Recently, interest has been focused on use of crystallography for lead optimization in the development for pharmacological inhibitors on MAP kinases. Further, some success has been gained in crystallizing the MAP kinase activators MAP2Ks and MAP3K kinase domains. This review describes the key methods that have been utilized to crystallize MAP kinases and MAP kinase pathway components.
丝裂原活化蛋白激酶(MAP激酶)和MAP激酶模块组件的X射线结构研究正在阐明激酶活性是如何被调节的,以及信号传导的特异性是如何赋予的。在过去十年中,MAP激酶已以其活性磷酸化形式或低活性非磷酸化形式结晶,以及在存在诸如对接肽和抑制剂等结合伴侣的情况下结晶。通过多种策略实现了结晶,包括磷酸化控制、编码序列修饰、引入用于纯化的标签以及使用多种细胞类型进行蛋白质表达。最近,人们的兴趣集中在利用晶体学在MAP激酶药理学抑制剂开发中进行先导优化。此外,在使MAP激酶激活剂MAP2Ks和MAP3K激酶结构域结晶方面已经取得了一些成功。本综述描述了用于使MAP激酶和MAP激酶途径组件结晶的关键方法。